LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
$1,142.85
-0.61% today · -3.43% 1W
Oct 2 close or latest
PreviewWhy it's moving
Underperforming without a clear catalyst yet
- LLY −0.61% on the last session vs SPY +0.74%: −1.3 pts of stock-specific move.
- 1 analyst action in the past 10 days (1 positive, 0 negative); latest: JP Morgan maintained Overweight, raised target $1,400 → $1,500.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
LLY against the S&P 500 components
| Window | Rank of 500 | Position | Gain | SPY gain |
|---|---|---|---|---|
| 1 day | #383 | -0.61% | +0.74% | |
| 1 week | #409 | -3.43% | -0.22% | |
| 1 month | #146 | -1.49% | +0.84% | |
| 3 months | #269 | -5.72% | +3.59% | |
| 6 months | #106 | +22.54% | +17.95% | |
| 1 year | #77 | +40.28% | +16.25% | |
| Overall | #211 | sum of the six window ranks, ranked again | ||
R500 ranks the stock's gain over each window against the S&P 500 components over the same window (#1 = best). Near-real-time during market hours.
Fundamentals Drug Manufacturers - General
| Metric | Value | Rank in S&P 500 | Rank in industry |
|---|---|---|---|
| Targeted Gain Median | 0.21 | #240 | #1 |
| fPE/tPE | 0.63 | #136 | #5 |
| PE/G | 1.13 | #163 | #2 |
| EV/Revenue | 13.36 | #37 | #1 |
| Gross Margin | 0.83 | #29 | #1 |
| Profit Margin | 0.34 | #37 | #1 |
| Revenue Growth | 0.48 | #35 | #1 |